Document:

Extension to Distibution and Supply Agreement

 
Exhibit 10.21

 
SUPPLY AND DISTRIBUTION AGREEMENT

 

	 1.	  	 PARTIES 

 
This Agreement is made between 
 
VIRANATIVE AB having its principal address at Tvistevägen 48, S-907 36 UMEÅ, Sweden. 
 
hereinafter referred to as “the Company” and

 
LABORATORIOS PISA, S.A. DE. C.V., a Mexican
Company having its registered Head Office in Av. España No. 1840, 44190 Guadalajara, Jalisco, Mexico, 
 
hereinafter referred to as “the Distributor”. 
 

	 2.	  	 PURPOSE 

 
The purpose of this Agreement is to grant the Distributor the exclusive right to market, sell and distribute the Product within the
Territory as defined in Exhibit A and in accordance with the terms and conditions expressed herein. 
 

	 3.	  	 DEFINITIONS 

 
In this Agreement, each time the following terms are used with initial capitals, their meanings shall be as specified hereunder.

 

	  	 –	  	 “Affiliated Companies” shall mean, in relation to a given company, any company which, directly or indirectly, controls, is controlled by or is under
common control with such company. 

 

	  	 –	  	 “Batch” and “Lot” shall mean a defined quantity of the Product which has been produced during a defined cycle of manufacture, and which is
identified by a unique production number. 

 

	  	 –	  	 “Contract Year” shall mean any period of l2 (twelve) consecutive calendar months following the Effective Date, as defined hereunder, or anniversary
thereof. 

 

	  	 –	  	 “Distribution Record” shall mean the record sheet detailing every shipment of the Product made by the Distributor to any of its customers including, but
not limited to, the customer’s name, address, batch number, number of bottles and date of shipment. 

 

	  	 –	  	 “Effective Date” shall mean the first day of the month following the month during which the Distributor is granted the “Product License”,
hereinafter “PL”, as here-under defined. 

 

	  	 –	  	 “Know How” shall mean any and all secret and confidential, technical, scientific, clinical, pharmacological and marketing information and data pending to
the 

 

1 of 15 

	  	   	  	 Products, developed and used by the Company and its Affiliated Companies and supplied to the Distributor under this Agreement and possible future additions.

 

	  	 –	  	 “Parties” shall mean the Company and the Distributor. 

 

	  	 –	  	 “Party” shall mean either the Company or the Distributor. 

 

	  	 –	  	 “PL” shall mean the Product License (or authorization under a physician prescription/named patient program) granted by the competent local medical
authorities for allowing the sale and distribution of the Product in the Territory. 

 

	  	 –	  	 “Price” shall mean the price of the Product as described in Exhibit B. 

 

	  	 –	  	  “Product” shall mean MultiferonTM  as chemically described and with the specification given in Exhibit C as modified from time to time according to the provisions of Exhibit B. 

 

	  	 –	  	 “Recall Operation” shall mean the operation for recalling the Product if it is suspected or known to be defective. 

 

	 4.	  	 APPOINTMENTS 

 
The Company hereby appoints the Distributor as its exclusive Distributor for the Product in the Territory (as defined in Exhibit A) and
Distributor hereby accepts such appointment in accordance with the terms and conditions herein expressed. 
 

	 5.	  	 PRODUCT PURCHASE AND SUPPLY COMMITMENTS 

 

	 5.1	  	 Distributor and Company agree to the purchase and supply of the following U.S. Dollar purchase and sales of Product over the initial term of this Agreement per the
following Performance Schedule, subject to the terms and conditions herein expressed: 

 
Performance Schedule 
 

	  	   	  	   	  Estimated Purchase and Sales in U.S. Dollars

	  Period

	   	  Duration

	   	  Distributor’s Forecast

	  First Period
	   	  First Consecutive 12 Months
	   	  $ 103,680.00 USD

	  Second Period
	   	  Second Consecutive 12 Months
	   	  $ 117,504.00 USD

	  Third Period
	   	  Third Consecutive 12 Months
	   	  $ 131,832.00 USD

	  Fourth Period
	   	  Fourth Consecutive 12 Months
	   	  $ 152,496.00 USD

	  Fifth Period
	   	  Fifth Consecutive 12 Months
	   	  $ 179,550.00 USD

	  Total
	   	  	   	  $ 685,062.00 USD

 

2 of 15 

 

	 5.2	  	 In case the Company provides to Distributor improvements to the Product, the Company and Distributor agree to negotiate in good faith increases on the sales for the
Performance Schedule stated in sub-paragraph 5.1 above. 

 

	 6.	  	 MEDICAL REGISTRATION 

 

	 6.1	  	 The Distributor shall take any and all necessary measures in order to obtain and maintain appropriate approvals from the local regulatory authorities which shall
include, but not be limited to, a PL and authorization to distribute the Product within the Territory. All costs and expenses associated with obtaining regulatory approval and the necessary permits to sell the Product in the Territory shall be borne
by the Distributor (as described in Exhibit A). 

 

	 6.2	  	 The PL has been approved prior to the execution of this Agreement. Such PL shall be maintained in force by the Distributor. If the PL expires due to causes
attributable to Distributor, the Company shall have the right to terminate the Agreement. 

 

	 6.3	  	 The Distributor shall pay all regulatory and governmental registration fees, all the annual registration maintenance fees and other fees required for the sale of
the Product as promulgated by any local, regional or national governmental authority. 

 

	 6.4	  	 In the event the Company is not free to disclose to the Distributor any information required by the responsible regulatory or other authorities, the Company shall
be obliged to make such secret information available to the authorities on the Distributor’s behalf at its own cost and expense. 

 

	 6.5	  	 The Company shall receive two (2) copies of all registration certificates, documentation for reimbursement and any other data or documentation forthwith upon their
issuance. The Distributor specifically agrees to provide the Company with copies of all correspondence with the registration authorities as well as any and all government agencies. Each party shall furnish the other with information on any observed
unexpected side effects, injury, toxicity or sensitivity reaction associated with the clinical use, studies, investigations or tests of the Product in accordance with Exhibit D, which contains a sub-agreement. 

 

	 6.6	  	 Distributor will at its own cost register the Product in the Territory and the Company will be the owner of the Registration in accordance with the existing rules
of the law. Distributor will complete the Registration of the Product in the Territory within six (6) months or earlier from the date in which the Company provides to Distributor the documents mentioned in paragraph 6.7. 

 

	 6.7	  	 In connection to the activities to be performed by Distributor for the registration of the Product according to this Section 6, the Company acknowledges that the
Product was previously registered in the Territory under the name Interferon-Alfanative and in favor of Alfanative AB, a Swedish entity of which the Company is currently its successor and beneficiary. Therefore, the Company shall send and grant to
Distributor, all documents and powers of attorney reasonably required by Distributor 

 

3 of 15 

 

	   	  	 in order that Distributor is able to request the change of the current PL and Registration of the Product, from the name Interferon-Alfanative to Multiferon.

 

	 7.	  	 COMPETITION, REPORTS, FORECASTS, INFORMATION AND INVENTORY 

 

	 7.1	  	 Obligation Not to Compete 

 
The Company shall refrain from selling the Product in the Territory and shall not grant nor appoint any other person or entity as
Distributor of the Product in the Territory. 
 
The
Distributor shall not manufacture, sell or distribute any interferon or other products which compete with the Product. The Distributor may, however, continue its business activities with respect to such products as it sells or distributes on the
date of signing this agreement as reflected in Exhibit E. The Distributor may nominate a Sub-Distributor upon submission of a request for approval and a copy of the draft Sub-Distributor Agreement which shall be submitted to the Company for its
approval. No Sub-Distributor agreement shall be valid without the written approval of the Company. 
 
From the date of this agreement, Distributor shall not distribute, directly or indirectly, any products containing the same active
ingredients as the Product. 
 
The Distributor
hereby warrants that it shall not seek customers for the Product outside the Territory, sell the Product outside the Territory, or establish any branch or maintain any distribution depot outside the Territory. The Sub-Distributor Agreement shall
require the Sub-Distributor to so warrant and the Distributor shall be accountable to the Company for enforcing this provision. 
 
The Distributor shall not have the right to produce the active ingredient of the Product. 
 

	 7.2	  	 Reports and Agreements 

 
The Distributor agrees to furnish the Company within 30 (thirty) days after each calendar quarter, or at such intervals as agreed upon by
the Company and the Distributor, with a true and accurate report on all sales of the Product in the Territory, as specified herein. The Distributor agrees to also furnish the Company with copies of all agreements, brochures, pamphlets and documents
which may relate to the Product including those developed, produced or used by the Distributor in connection with the sale of the Product. The Distributor agrees to design all promotional materials according to company’s branding guidelines.
The Distributor agrees not to use any such material without the Company’s prior written approval. Upon submission, the Company agrees to respond promptly without any unnecessary delay and consent shall not be unreasonably withheld.

 
At any time upon reasonable request of the
Company, Distributor agrees provide the Company with information, including but limited to, selling prices, market trends, competitive environment and competitor’s prices, technical or commercial information useful for the adaptation of the
Product to market requirements. 
 

4 of 15 

 
Distributor
agrees to send to the Company a quarterly report on market developments in the Territory and Distributor’s sales progress relating to the Product. 
 
At any time and upon reasonable request of the Company, Distributor shall permit the Company’s representative(s) to accompany
Distributor’s representative(s) on visits made to customers in order to have the Company better acquainted with the specificity of the market for the Product in the Territory. The Company agrees to send a letter of notice of at least 30
calendar days prior to the visits. The Company agrees not to circumvent the Distributor during the term hereof and any renewal. 
 

	 7.3	  	 Forecasts 

 
Following PL approval, the Distributor shall submit to the Company each calendar quarter during each calendar year a rolling forecast for
the following 4 (four) quarters showing the planned purchase quantities of the Product. The Distributor shall place its firm orders for the Product for the following quarter with the rolling forecast. Before approval by the Company, the Distributor
shall submit each month a rolling forecast for the following twelve months connected to firm orders for the Product for the following quarter. 
 

	 7.4	  	 Information 

 
The Company shall provide the Distributor with all presently available data, information and documents necessary for the carrying out of
this Agreement, including technical documents and advertising material. The Company shall provide the Distributor with any significant Know How related to the Products, in addition to that already provided as of the date hereof, which may be or
shall become available to the Company, whether originated by the Company or its Affiliated Companies, and which the Company is free to disclose. 
 

	 7.5	  	 Inventory 

 
The Distributor shall buy and maintain, at his own cost, an inventory of the Product equaling no less than the amount forecasted for the
following quarter and see to it that the Product is kept in good condition and that all reasonable precautions are taken to prevent its deterioration at its own cost, expense and liability. 
 

	 8.	  	 THE DISTRIBUTOR 

 

	 8.1	  	 Independency 

 

	 8.1.1	  	 For Its Own Account 

 
The Distributor shall buy and sell the Product in its own name and for its own account and act in all respects as an independent
contractor. The Distributor shall organize the distribution of the Product in such a manner as to most effectively promote the sale of the Product and maintain a level of product support necessary for the proper selling, marketing and distribution
of the Product. 
 

5 of 15 

 

	 8.1.2	  	 Independent Contractor 

 
This Agreement does not designate the Distributor to be the agent, partner or legal representative of the Company for any purpose
whatsoever, and the business conducted by the Distributor pursuant to this Agreement with third parties shall be wholly at the Distributor’s own risk and account as an independent contractor. 
 
The Distributor is not granted any right or authority to
assume or create any obligation or responsibility, express or implied, on behalf of or in the name of the Company or to bind the Company in any manner whatsoever. 
 

	 8.2	  	 Unfair Competition and Infringement of Rights 

 
The Distributor shall inform the Company of all acts of unfair competition and of all infringement of patents, trade mark, trade names, or
similar rights of the Company which have come to its attention to the extent that the rights of the Company have been violated. If requested by the Company, the Distributor shall assist the Company at the Company’s expense in any action or
litigation involving such acts or infringements. 
 

	 8.3	  	 Distribution Records 

 
In order to enable the Company to comply with the requirements of the European Code of Good Manufacturing Practice (Volume IV of the Rules
Governing Medical Products in the European Community), the Distributor shall keep Distribution Records for each Batch of the Product sold to the customers. This information shall be made available to the Company in case of Recall Operation, within
two working days, by sending a fax, confirmed by a letter, to: 
 
ViraNative AB 
Tvistevagen 48 
S-907 36 Umeå 
Sweden 
 
Tel no: 46-90-172250 
Fax no: 46-90-193736 
 

	 9.	  	 CONDITIONS OF SALE 

 

	 9.1.1	  	 Purchase Orders 

 
The Distributor shall send all orders for the Product to be purchased under this Agreement to the Company together with adequate delivery
instructions. The Company shall deliver the Products to Distributor in a period no longer than three (3) months from receipt of the relevant Purchase Order. Orders presented by the Distributor shall bind the Company after written confirmation of
acceptance thereof by the Company which shall be sent to Distributor upon 3 (three) business days following receipt of the Purchase Order. Silence in these regards following such three-day period, shall be deemed as acceptance of the Purchase Order
and its terms. 
 

6 of 15 

 

	 9.1.2	  	 Distributor warrants that before accepting from customers in the Territory any orders containing penalties for delayed deliveries, it will request the
Company’s approval, furnishing simultaneously to the Company all relevant details. Distributor will be at the liberty of accepting such order if Distributor does not receive notice from the Company within fifteen (15) business days following
Distributor’s request. The Parties agree to share the cost of any penalties due, if any, in case there is failure from both parties. Otherwise, penalties will be paid by the Company or by the Distributor, whoever is at fault for the delay in
delivery. 

 

	 9.2	  	 Price Guidelines 

 

	 9.2.1	  	 Price and Conditions 

 
The Distributor shall purchase the Product at prices and on conditions set forth by the Company from time to time in Exhibit B.
Notwithstanding the above, any price increase will be mutually discussed in good faith by the Parties, and Exhibit B shall be deemed as amended accordingly. 
 

	 9.2.2	  	 Payment Terms 

 
The Distributor shall pay the Company for the Product supplied according to payment terms as set forth in Exhibit B. 
 

	 9.3	  	 Advertising and Promotion 

 

	 9.3.1	  	 Best Efforts 

 
The Distributor shall use its best efforts and diligence in promoting and initiating effectively the sales of the Product throughout the
whole of its Territory. 
 

	 9.3.2	  	 Advertising and Promotional Activities 

 
The Distributor shall ensure the advertising and the promotion of the Product and, to a reasonable extent, the participation in
conventions, trade shows and exhibitions held in the Territory. The costs of advertising and promotion are to be borne by the Distributor. All advertising and promotional copy shall be submitted to the Company for its written approval prior to
release. 
 

	 9.3.3	  	 Conformity with Applicable Laws 

 

	 9.3.4.	  	 The Distributor shall be responsible for any advertising and promotional material for the Product and for their conformity with applicable laws and regulations, as
well as with the Company’s branding guidelines. 

 

	 9.3.5	  	 Distributor shall be responsible for delivering copy to the Company of any text in the local language that may be required under law, rule or regulation.

 

7 of 15 

 

	 10.	  	 GENERAL PROVISIONS 

 

	 10.1	  	 Trade Secrets 

 
The Distributor shall not, even after the expiration of this Agreement, use or communicate to any third party any trade secrets which the
Distributor has come to know in one way or another through its work for the Company. The obligation shall cease at the end of a period of (five) 5 years from the date of the termination or expiration of this Agreement; however, the obligation shall
not cease for any reason prior to the end of the first (ten) 10 years after the signing of the Agreement. 
 
The Distributor assumes the responsibility, liability and obligations that its employees and any Sub-Distributor and its employees shall
preserve the secrecy of trade secrets with respect to third parties. 
 

	 10.2	  	 Trademarks 

 
Trademarks, Tradenames and Copyrights used by the Distributor for the Product shall be the property of the Company, and the Distributor
agrees to use only such Trademarks, Tradenames and Copyrights as indicated and approved in writing by the Company. It is agreed that the Company’s registered trademark of the Product, MultiferonTM may be used in the Territory, provided a registration of these trademarks will be obtainable and maintained. 
 
The Distributor shall not, without the Company’s prior
written consent, use the Company’s corporate name, telegraphic address, graphic or other trademarks, whether during the maintenance of or after the termination of this Agreement. 
 
The Distributor shall not register or attempt to register for any purpose any trade-mark, tradename,
copyright, name, title or expression of the Company as used on the Product or any other trademark or any tradename which is similar thereto. 
 
Electronic emails may be considered adequate consent if originated at the Company’s premises. 
 
Should Distributor become aware of any breach on the part of
third parties of Patents, Trademarks or Know How relative to the Products, it shall immediately inform the Company and shall provide the Company with the widest assistance in order to protect such rights. 
 
Distributor undertakes to cooperate with the Company in
preventing all breaches of Patents, Trademarks or Know How relative to the Products upon the terms of the subsequent paragraph and in any event to prevent said breaches using its best efforts. 
 
In the case of possible breaches of Distributor, Trademarks or
Know How on the part of third parties, Distributor undertakes to cooperate with the Company and with the Company’s attorneys in order to allow the correct carrying out of legal actions. 
 
The Company shall inform the Distributor of all acts of unfair
competition and of all infringements of Patents, Trademarks, Tradenames or similar rights of Distributor which have come to its attention to the extent that the rights of the Distributor have 
 

8 of 15 

 
been violated.
If requested by Distributor, the Company shall assist Distributor at Distributor’s expense in any action or litigation involving such acts or infringements. 
 
Distributor shall immediately report to the Company any actual or threatened infringement or imitation of
said intellectual properties, which it may learn, by giving written information of all details available concerning said infringement. 
 
Distributor shall not institute or bring legal actions or proceedings against such infringers without prior written authorization from the
Company. 
 
Costs and expenses for legal actions or
proceedings shall be borne by the Company, which, however, will not be obliged to act. 
 

	 10.3	  	 Assignment 

 
The Parties shall have the right to assign this Agreement, upon written notice to the other Party but without the prior consent such
Party, to: 
 

	  	 a)	  	 any of its Affiliated Companies; or 

 

	  	 b)	  	 its successors in interest as a result of a statutory merger or consolidation; or 

 

	  	 c)	  	 a company acquiring all or substantially all of the Company’s business and assets including the part concerned by this Agreement. 

 
Each party reserves the right to terminate this Agreement
whenever the control of the other party passes over to another party other than the party controlling it at the time of signature of this present Agreement. 
 

	 10.4	  	 Force Majeure 

 
If due performance of this Agreement by either party is affected in whole or in part by reason of any event, omission, accident, general
shortage of commodities, legal circumstances or other matter beyond the reasonable control of such party, it shall give prompt notice thereof to the other party and shall be under no liability for any loss, damage, injury or expense suffered by the
other party for this reason. Both parties shall use all reasonable efforts to avoid or overcome the causes affecting performance and the party whose performance is affected by such force majeure shall fulfill all outstanding obligations as soon as
possible. 
 

	 10.5	  	 Warranties and Liability 

 

	 10.5.1	  	 The Company warrants to the Distributor that the Product delivered hereunder shall comply with the specification set forth in the PL and consistent with Exhibit C.

 

	  	 a)	  	 If the parties agree that a certain lot of the Product supplied hereunder fails to meet said specification or is otherwise defective or if such lot is recognized as
defective by an independent laboratory as provided for hereafter in this section, and unless otherwise mutually agreed upon, the Distributor shall send such lot back to the Company and the Company shall replace it at its own expense, including the
freight back, with a new lot of the Product conforming with said specification. The Company shall also be held responsible for any 

 

9 of 15 

 

	  	   	  	 liability the defective merchandise may cause, if and when it is proven that the liability has been derived from manufacturing defect and not from handling or
storage conditions by the distributor or third parties. 

 

	  	 b)	  	 If the parties fail to agree that a certain lot of the Product supplied hereunder meets said specification, Distributor may request an expert appraisal by an
independent laboratory, not associated with any of the parties hereto, to determine whether the Product complies with said specification. Should the Company disagree with regard to the choice of laboratory, the Company has the right to request that
the laboratory is appointed by the International Chamber of Commerce provided that the Company informs the Distributor within two weeks after having been informed by the Distributor about its choice of laboratory, that the Company requests that the
appraisal shall be carried out by a laboratory appointed by the Chamber. The report of the laboratory shall be conclusive and binding on the parties hereto. All expenses related to such appraisal shall be borne by the party, whose opinion of which
has been found not to be correct. No other warranties, expressed or implied, including, without limitation, merchantability or fitness for a particular purpose, are made or will be deemed to have been made by the Company regarding the Products,
except to the extent expressly stated herein. Neither the Distributor, nor any of its employees, agents or representatives is authorized to give any warranties or make any representations on behalf of the Company In no event shall the Company be
held liable for any lost profits or any other incidental or consequential damages in connection with any claims arising out of or related to any Products supplied by the Company to the Distributor. 

 

	 10.5.2	  	 The Distributor shall indemnify and hold the Company harmless from and against any and all liability, damage, loss, cost or expense arising out of or resulting from
any claims made or suits brought against the Company or the Distributor, which arise out of or result from the Distributor’s negligent act or omission in the marketing, selling or distribution of the Product. 

 

	 10.5.3	  	 The Distributor has, and shall at all times during the term of this Agreement and for a period of two years thereafter, have full insurance coverage with reputable
and sound insurance covering all and any risks, including (without limitation) any liabilities to third parties and the public (including without limitation product liability). The Company will have the right to review the insurance policies in
order to make sure the Distributor’s insurance coverage is sufficient. 

 

	 10.5.4	  	 The Company represents that it will add the Distributor as a Named Insured on its current International Liability Insurance Policy held with MedMarc Casualty and
Insurance Company under Policy Number 00FL020010 within 30 days from the date of execution of this agreement. 

 

	 10.5.5	  	 Compliance with Applicable Laws 

 
The Distributor agrees that it will, on its own comply with all laws, statutes and ordinance in the Territory relating to the import and
sale of the Product and agrees to 
 

10 of 15 

 
indemnify and
hold the Company harmless in the event that any claim is made against it by reason of the Distributor’s failure to so comply. In particular, the Distributor agrees to comply with all safety laws and regulations in the Territory relating to the
Product and the Company agrees to provide all necessary information and assistance to the Distributor to enable it to so comply. 
 

	 10.5.6	  	 The Company agrees that it will comply with the laws of the Territory regarding the labeling and packaging of the Products, which will be properly labeled and
packed when delivered to the Distributor. 

 

	 10.6	  	 Taxes 

 
The Distributor shall pay all excise or sales taxes that may be required to be paid by the Company or the Distributor by any statute,
ordinance or regulation of any taxation authority. In the event that the Company is required to or does pay any of such taxes, the Distributor, upon being informed of such payment, shall at once repay the amount thereof to the Company. The
Distributor, unless prohibited by any such statute, ordinance or regulation, shall have the right to require any dealer or Sub-Distributor handling such goods to pay any such excise or sales taxes on the goods so handled by him. 
 

	 11.	  	 DURATION AND TERMINATION 

 

	 11.1	  	 Duration 

 
This Agreement shall have immediate force and effect and shall remain in effect until the completion of a ten (10) year Period, and shall
continue thereafter for an additional three (3) year term and continue thereafter for two automatic three (3) year terms unless and until terminated by either party giving to the other six (6) months notice in writing prior to the end of the Initial
Term or any Subsequent Term. 
 

	 11.2	  	 Termination 

 

	 11.2.1	  	 Failure to Fulfill Obligations or to Obtain or Maintain PL 

 
This Agreement may be terminated with three (3) months written notice forthwith by either party if the other party fails to fulfill any of
its obligations under this Agreement and such default is not remedied within thirty (30) days of the date on which a written notice thereof has been dispatched to the defaulting party or if the Distributor fails to obtain or maintain the PL as set
forth in Article 6, Medical Registration. 
 
Notwithstanding the foregoing, in case Distributor does not achieve the volumes of sales stated on the Performance Schedule in section 5.1 herein, for causes satisfactorily evidenced and justified to the Company and not attributable
to Distributor (i.e. material adverse effects on the market or economic situation in the Territory), such event shall not be deemed as a cause for termination of this 
 

11 of 15 

 
Agreement and,
therefore, the Company may not terminate this agreement for this specific situation. 
 

	 11.2.2	  	 Termination for Bankruptcy or Insolvency 

 
This Agreement may be terminated immediately in the event that either party is declared insolvent, is adjudged bankrupt or files a
petition for bankruptcy or reorganization under any bankruptcy law, is expropriated or sequestrated or submits or has to submit to any other administrative or judicial measures of control. 
 
Insolvency is defined to mean the inability to pay debts, as they become due and the excess of liabilities
over assets. 
 

	 11.2.3	  	 Termination for Loss of License to Sell Product 

 
The Company shall have a right to terminate this Agreement with immediate effect should the Company’s license to sell the Product be
withdrawn. 
 

	 11.2.4	  	 Termination without cause 

 
If this Agreement is terminated by the Company without cause, the Company shall reimburse Distributor for all expenses incurred by
Distributor in connection to clinical trials of the product. 
 

	 11.3	  	 Effect of Termination 

 
On the termination of this agreement, the Distributor shall return, without delay, all registration and permission documents to the
Company together with all formulas, manufacturing procedures and other confidential documentation which the Distributor has obtained from the Company. The Distributor agrees that it shall not make any further use of this documentation. The Company
shall have the option to repurchase any paid unsold Product at prices paid by the Distributor to the Company. 
 

	 11.4	  	 Notice of Termination 

 
Notice of termination shall be in writing and shall be deemed given: (i) upon personal delivery to the appropriate address, (ii) upon
delivery to the appropriate address if sent by certified or registered mail, (iii) one business day after the date of deposit with an express mail overnight courier, or (iv) if by facsimile, upon the transmittal of same with printed confirmation of
receipt. 
 

	 11.5	  	 Exclusive and Non-Exclusive Distribution Rights 

 
In the event Distributor fails to achieve seventy percent (70%) of the sales figures set forth under “Performance Standards” in
paragraph 5.1, then the exclusive distribution rights as set forth herein may be cancelled by the Company, and shall notify the Distributor with a written notice of no less than three (3) months prior to the cancellation date, unless, as stated in
clause 11.2.1, the lack of achievement is due to 
 

12 of 15 

 
causes
satisfactorily evidenced and justified to the Company and not attributable to Distributor. 
 

	 11.6	  	 Termination Compensation 

 
Neither party hereto shall be liable to the other for any termination compensation whether based on goodwill, loss of income or otherwise.

 

	 12.	  	 FINAL PROVISIONS 

 

	 12.1	  	 Governing Law 

 
This Agreement shall be governed by the laws of Sweden 
 

	 12.2	  	 Language 

 
The English text of this Agreement shall prevail. 
 

	 12.3	  	 Arbitration 

 
Any dispute in connection with this agreement shall be definitely and incontestably solved by the arbitration and conciliation statute
according to the rules of the International Chamber of Commerce in Paris by three arbitrators who will be designated according to this statute. 
 
The arbitration seat will be in Paris, the arbitration language will be English and the Swedish law will be applicable to the merits of
the disputes. 
 

	 12.4	  	 Modifications 

 
All modifications and amendments to this Agreement shall be in writing and signed by the Parties. 
 

	 12.5.	  	 Notices and Communications 

 
All notices in connection with this Agreement shall be in writing and be in the English language, as shall all other written
communications and correspondence, and may be given by personal delivery, prepaid registered airmail letter, facsimile, or telegram addressed to the Party required or entitled to receive the same at its address or facsimile number set out below, or
to such other address or facsimile number as such Party shall have designated by like notice to the other Party. Notice of termination of this Agreement if given by facsimile or telegram shall be confirmed by prepaid registered airmail letter dated
and posted within 24 hours. The effective date of any notice if served by personal delivery, facsimile, or telegram shall be deemed the first business day in the city of destination following the dispatch and if given by prepaid registered airmail
letter only, it shall be deemed served seven days after the date of posting. 
 

	 12.6	  	 Exhibits 

 

13 of 15 

 
All Exhibits
attached hereto shall be made a part of this Agreement. 
 

	 12.7	  	 No Waiver 

 
The omission by either Party to exercise any right hereunder shall not constitute a waiver thereof and shall not prevent the subsequent
enforcement of that right and shall not be deemed to be a waiver of any subsequent right. 
 

	 12.8	  	 Survival of Provisions 

 
The provisions of this Agreement shall survive its termination for so long as may be necessary to give efficacy thereto. 
 

	 12.9	  	 Entire Agreement 

 
This Agreement, which includes the Exhibits attached hereto, contains the entire understanding and supersedes all prior agreements of the
parties with respect to the transactions contemplated hereby, especially, this Agreement substitutes the Agreement executed by and between Alfanative AB and Distributor dated as of July 14, 1998. There are no agreements, promises, warranties,
covenants or understandings other than those expressly set forth herein. 
 

	 12.10	  	 Invalidity 

 
Any provision of this Agreement that is invalid or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the
extent of such invalidity or unenforceability without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction. 
 

14 of 15 

 
IN WITNESS WHEREOF the parties
hereto have hereunto set their hands the day and year indicated below. 
 

	  VIRANATIVE AB
	  	  	  	  LABORATORIOS PISA, S.A. DE C.V.

	
	  By:
	  	  /s/ Gerald Smith

	  	  	  	  By:
	  	  /s/ Alfonso Alvarez Paramo

	  	  	  Gerald Smith, Chairman
	  	  	  	  	  	  Mr. Alfonso Alvarez Páramo, General Director

	
	  Print:
	  	                                       
    Date 1/9/03
	  	  	  	  Date:
	  	

 
 

15 of 15Summary of Proposed Terms

Exhibit 10.1 
 
 
Tangram Enterprise Solutions,
Inc. 
Summary of Proposed Terms for Revolving Line of Credit and Demand Loan 
 
February 13, 2003 
 
Revolving Line of Credit 
 

	  Borrower:
	   	  Tangram Enterprise Solutions, Inc. (the “Company”)

	
	  Lender:
	   	  Safeguard Delaware, Inc. (“Safeguard”)

	
	  Principal Amount:
	   	  $1,350,000 revolver, to be borrowed, repaid and reborrowed by the Company at its discretion until the Maturity
Date

	
	  Type of Security:
	   	  Promissory Note in the form of Exhibit A attached hereto (the “Revolver”).

	
	  Interest:
	   	  prime rate plus 1% per annum (on the basis of a 360-day year)

	
	  Repayment Terms:
	   	  Principal payable on the earlier of one year from the date of the Revolver or a change of control (“Maturity
Date”). Lender shall notify Borrower at least 90 days prior to the one-year anniversary from the date of the Revolver as to Lender’s intention to renew the Revolver. If Lender determines not to renew the Revolver, Borrower must repay
outstanding principal and any accrued and unpaid interest within six months from the one-year anniversary.

	
	  	   	  In addition, upon the closing of a sale of debt or equity securities by the Company, the Company shall apply the
proceeds (net of underwriting discounts and commissions) in excess of $2,500,000 first to the repayment of the then outstanding obligations under the Revolver

	
	  	   	  Interest payable quarterly in arrears

	
	  	   	  Prepayment without penalty or premium

	
	  Events of Default:
	   	  Default in payment of principal or interest

	
	  	   	  An event of default by Company under any other obligation

	
	  	   	  Certain bankruptcy, insolvency and other similar events with respect to the Company

	
	  	   	  Default rate – prime rate plus 3% per annum

 

1 

 
Demand Loan

 

	  Borrower:
	   	  Company

	
	  Lender(s):
	   	  Safeguard and TBBH Investments Europe AG (successor in interest to Axial Technology Holding AG)
(“Axial”).

	
	  Principal Amount:
	   	  $1,700,000, provided by Lenders as follows:

 

	  Safeguard                                    
      
	   	  $
	  650,000

	  Axial
	   	  $
	  1,200,000

	  	   	
	

	          Total                             
           
	   	  $
	  1,850,000

 

	
	  Type of Security:
	   	  Promissory Notes in the form of Exhibit B attached hereto (the “Notes”)

	
	  Interest:
	   	  prime rate plus 1% per annum (on the basis of a 360-day year); provided however, that the Axial Note shall only
accrue interest on $500,000 of principal until the first anniversary of the date of the Note and thereafter shall accrue interest on the entire outstanding principal

	
	  Repayment Terms:
	   	  Principal payable on the earlier of six months after the date of demand, which may be made anytime after one year
from the date of the Notes or a change of control (“Maturity Date”) In addition, upon the closing of a sale of debt or equity securities by the Company, the Company shall apply the proceeds (net of underwriting discounts and commissions)
in excess of $2,500,000 first to the repayment of the then outstanding obligations under the Revolver then the Notes

	
	  	   	  Interest payable quarterly in arrears

	
	  	   	  All payments on the Notes shall be allocated pro-rata to each of the Lenders based upon the total outstanding
principal and interest balance of the Note at the time of the payment

	
	  	   	  Only if there are no amounts outstanding under the Revolver, prepayment without penalty or
premium

	
	  Events of Default:
	   	  Default in payment of principal or interest

	
	  	   	  An event of default by Company under any other obligation

	
	  	   	  Certain bankruptcy, insolvency and other similar events with respect to the Company

	
	  	   	  Default rate – prime rate plus 3% per annum

 
 
 

2 

Other Provisions 
 

	  Note Exchange:
	   	  The Revolver and Safeguard Note are being issued in replacement of that certain Second Amended Revolving Note, dated
September 11, 1997, as amended on February 20, 2001 made by the Company in favor of Safeguard Scientifics, Inc. The Axial Note is being issued in replacement of that certain Promissory Note, dated February 13, 2001 made by Borrower in favor of
Axial.

	
	  Expenses:
	   	  The Company will bear the expenses of the Lenders and of the Company incurred in connection with this transaction.
The Lenders portion not to exceed $25,000.00.

	
	  Publicity:
	   	  Any press release or other public statement issued by any party relating to this letter or the transactions
contemplated shall be approved in advance by all parties and shall contain appropriate references to each such party who desires such references.

	
	  Target Closing:
	   	  On or before February 17, 2003. If this term sheet is not executed and closing has not occurred by such date, this
proposal will be deemed withdrawn.

	
	  Preferences:
	   	  In accordance with U.S. law, in the event of a liquidation of the Company, the holders of the Revolving Note and the
Demand Notes will be paid prior to any payments made to holders of equity securities (preferred or common). The Demand Note holders agree that any repayments shall first be applied to the repayment of the Revolving Note and then pro rata as between
the Demand Note holders. As provided in the Company’s Statement of Designations, Preferences and Rights of the Series F Preferred Stock, a change of control of the Company shall be deemed a liquidation.

 

3 

 
This is neither an offer nor a
binding commitment. A binding commitment will only be made pursuant to the execution of definitive loan agreements mutually acceptable to all parties and only upon satisfaction of the following conditions: 
 
Please do not hesitate to contact us if you have any questions or comments
regarding this letter. 
 

	  SAFEGUARD DELAWARE, INC.

	
	  By:
	  	  /s/ Christopher J. Davis

	  Name:
	  	  Christopher J. Davis

	  Title:
	  	  Managing Director and Chief Financial Officer

 
 

	  TBBH INVESTMENTS EUROPE AG
  (successor in title to Axial Technology Holding AG)

	
	  By:
	  	  /s/ David P. Kennealy

	  Name:
	  	  David P. Kennealy

	  Title:
	  	  Director

 
As
of this 13th day of February, 2003, the undersigned hereby acknowledges that this term sheet is acceptable as a basis for negotiating the Revolver and Notes and agrees to be legally bound by those particular terms under the heading
“Publicity”. 
 

	  TANGRAM ENTERPRISE SOLUTIONS, INC.

	
	  By:
	  	  /s/ Norman L. Phelps

	  Name:
	  	  Norman L. Phelps

	  Title:
	  	  President and CEO

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]